| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 690.9 | 624.9 |
| Profit before tax | 96.7 | 83.5 |
| Net income | 71.6 | 64.2 |
| EPS (diluted, $ a share) | $5.45 | $4.46 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +11.5% |
|---|---|
| Revenue, year on year | +10.6% |
| Operating margin | 14.0% |
10-Q filed with the SEC, NYSE: CHE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Chemed Corp: key numbers
- Share price
- $549.45Close, Nov 16
- Market cap
- $7.15B
- Shares outstanding
- 13.01MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Home Health Care ServicesSIC 8082
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Chemed Corp
All →Chemed EVP Spencer S. Lee Sells $548K of Stock
Spencer S. Lee, EVP, sold 1,000 shares of Chemed Corp at $547.61 a share, worth $548K in total on Nov 11, 2026. Shares held after the trade: 12,931 (-7.2%).
- Value
- $548K
- Shares
- 1,000
- Price
- $547.61
- Role
- EVP
- Holding change
- -7.2%
- Trade date
- Nov 11, 2026
Chemed president and CEO Kevin J. Mcnamara Sells $1.08M of Stock
Kevin J. Mcnamara, president and CEO, sold 2,000 shares of Chemed Corp at $537.90 a share, worth $1.08M in total on Nov 3, 2026. Shares held after the trade: 82,220 (-2.4%).
- Value
- $1.08M
- Shares
- 2,000
- Price
- $537.90
- Role
- president and CEO
- Holding change
- -2.4%
- Trade date
- Nov 3, 2026
Chemed EVP Spencer S. Lee Sells $494K of Stock
Spencer S. Lee, EVP, sold 920 shares of Chemed Corp at $537.17 a share, worth $494K in total on Nov 2, 2026. Shares held after the trade: 13,931 (-6.2%).
- Value
- $494K
- Shares
- 920
- Price
- $537.17
- Role
- EVP
- Holding change
- -6.2%
- Trade date
- Nov 2, 2026
Chemed Financial Results
Chemed Corporation reported third-quarter 2026 consolidated revenue of $690.9 million, a 10.6% increase year-over-year, driven by strong performance in its VITAS Healthcare segment. GAAP diluted EPS rose 22.2% to $5.45, while the VITAS segment saw a 12.2% increase in net patient revenue and a significant expansion in Adjusted EBITDA margins.
- Term
- Q3 2026
Chemed president and CEO Kevin J. Mcnamara Sells $1.03M of Stock
Kevin J. Mcnamara, president and CEO, sold 2,000 shares of Chemed Corp at $513.45 a share, worth $1.03M in total on Sep 28, 2026. Shares held after the trade: 66,418 (-2.9%).
- Value
- $1.03M
- Shares
- 2,000
- Price
- $513.45
- Role
- president and CEO
- Holding change
- -2.9%
- Trade date
- Sep 28, 2026
Chemed president and CEO Kevin J. Mcnamara Sells $1M of Stock
Kevin J. Mcnamara, president and CEO, sold 2,000 shares of Chemed Corp at $501.40 a share, worth $1M in total on Sep 18, 2026. Shares held after the trade: 68,418 (-2.8%).
- Value
- $1M
- Shares
- 2,000
- Price
- $501.40
- Role
- president and CEO
- Holding change
- -2.8%
- Trade date
- Sep 18, 2026